The Pro Medicus (ASX: PME) share price dropped 13% after it reported another set of strong results, albeit with slower half-on-half growth.
Pro Medicus (ASX:PME)
Pro Medicus (ASX: PME) is a radiology software company founded in Melbourne in 1983 by friends and fellow wine connoisseurs Sam Hupert and Anthony Hall.
Pro Medicus (ASX: PME) was listed in 2000 during the tech bubble at a Pro Medicus IPO price of $1.15. The Pro Medicus share price was languishing until it acquired Visage Imaging from Mercury Computer Systems in 2009, selling just part of the acquired technology for a profit, not long after.
Visage Imaging has benefitted from ownership by Pro Medicus. Long serving General Manager of Visage Imaging, Malte Westerhoff lead the team of developers in Berlin, to develop Visage 7 viewer, which counts won the business of top notch US teaching hospitals like Mayo Clinic.
The FY 2023 Pro Medicus (ASX: PME) AGM further demonstrated the high quality of the business and the good nature of the leadership group.
Why did the Pro Medicus share price spike to a record of $78.85 this morning and what is the relevant news for Pro Medicus (ASX: PME)?
The FY 2023 Pro Medicus Results showed record profits and a strengthening competitive advantage, with new products soon to be commercialised.
Claude, Matt and Andrew interview Pro Medicus CEO Sam Hupert.
The H1 FY 2023 Pro Medicus (ASX: PME) Results showed record half year revenue and profit. While the outlook is rosy, cash flow was less ideal.
The 2022 Pro Medicus AGM highlighted the strong competitive advantage of its key product, Visage.
Pro Medicus results show record revenue and profit in FY 2022. Is the Pro Medicus (ASX: PME) competitive advantage improving?
I use watchlists with target desired buy prices to help me take advantage of market volatility in a calm and measured way.
A detailed look at the Pro Medicus major customer list, and why it needs both integrated delivery networks, and academic teaching hospitals.
My analysis of the Pro Medicus half year results suggest that the business is improving in quality as it grows.
Talking Stocks: Damstra (ASX: DTC), Pro Medicus (ASX: PME), Tesla and Peloton on the Rask Invest Podcast
Owen Raszkiewicz, Anirban Mahanti, and Claude Walker sit down to chat Pro Medicus (ASX:PME), Damstra (ASX:DTC), Tesla and Peloton stocks.
ASX superstar stock Pro Medicus (ASX:PME) has reported record results for FY2021, but how does the future look?
The Pro Medicus share price fell today (ASX: PME), despite stronger profits and record revenue, with volumes bouncing back as covid recedes.
It’s easy to say that the Pro Medicus share price is very optimistic, but is it high enough to warrant selling some shares?